Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: February 2015

20 - Stimulant medication in children and adolescents

References

1. WigalS, SwansonJM, FeifelD, et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43(11):1406–14.
2. FindlingRL, LopezFA, eds. Efficacy of transdermal methylphenidate with reference to Concerta in ADHD. 52nd Annual Meeting of American Academy of Child and Adolescent Psychiatry; 2005 October 18–23; Toronto, Canada; 2005.
3. WilensTE, HammernessP, MartelonM, et al. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71(5):548–56.
4. WilensTE, BoellnerSW, LopezFA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):700–8.
5. JasinskiDR, KrishnanS.Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410–18.
6. PatrickKS, MarkowitzJS.Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol. 1997;12:527–46.
7. GualtieriCT, WarginW, KanoyR, et al. Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry. 1982;21(1):19–26.
8. MarkowitzJS, PatrickKS.Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?J Clin Psychopharmacol. 2008;28(3):S54–61.
9. ZhuHJ, PatrickKS, YuanHJ, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008;82(6):1241–8.
10. ZhuH, WangJS, DonovanJL, et al. Interactions of attention-deficity/hyperactivity disorder therapy agents with the efflux transporter P-glycoprotein. Eur J Pharmacol. 2008;578:148–58.
11. GreenhillLL, PliszkaS, DulcanMK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl):26S–49S.
12. VitielloB.Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology. 2007;191:5–13.
13. AngristB, CorwinJ, BartlikB.Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry. 1987;22:1357–68.
14. SachdevP, TrollerJ.How high a dose of stimulant medication in adult attention deficit hyperactivity disorder?Aust N Z J Psychiatry. 2000;34:645–50.
15. BiedermanJ, MickE, SurmanC, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829–35.
16. StevensJR, GeorgeRA, FusilloS, SternTA, WilensTE.Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation. J Child Adolesc Psychopharmacol. 2010;20(1):49–54.
17. PliszkaS.Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.
18. WilensT, PelhamW, SteinM, ConnersCK, AbikoffH. ADHD treatment with a once-daily formulation of methylphenidate hydrochloride: a two-year study. 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA; 2003.
19. JensenP, HinshawSP, SwansonJM, et al. Findings from the NIMH multimodal treatment study of ADHD: implications and applications for the primary care providers. J Dev Behav Pediatr. 2001;22:60–73.
20. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD [see comments]. Arch Gen Psychiatry. 1999;56(12):1073–86.
21. StevensJR, AlpertJE, FavaM, RosenbaumJ.Psychopharmacology in the medical setting. In: SternTA, FricchioneGH, eds. Massachusetts General Hospital Handbook of General Hospital Psychiatry. Amsterdam: Elsevier Science Publishers. 2010; 441–66.
22. SpencerT, BiedermanJ, WilensT, et al. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–32.
23. SpencerT, BiedermanJ, WilensT. Pharmacotherapy of ADHD: A life span perspective. In: OldhamJ, RibaM, eds. American Psychiatric Press Review of Psychiatry. Washington, DC: American Psychiatric Association. 1997; 87–128.
24. FaraoneSV, BiedermanJ, SpencerT, AleardiM.Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med. 2006;8(4):4.
25. ByrneJM, BawdenHN, DeWolfeNA, BeattieTL.Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. J Clin Exp Neuropsychol. 1998;20(5):617–27.
26. GreenhillLL, AbikoffH, KollinsS, WigalS, SwansonJ, GroupPCS. Outcome results from the NIMH multi-site Preschool ADHD Treatment Study (PATS). 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2004 October 19–24; Washington, DC; 2004.
27. WilensTE.Treatment and assessment of ADHD in children and adolescents. In: BiedermanJB, ed. ADHD Across the Lifespan: An Evidence-Based Understanding from Research to Clinical Practice. Hasbrouck Heights, NJ: Veritas Institute for Medical Education. 2006; 176–206.
28. WilensT, McBurnettK, BuksteinO, et al. Multisite, controlled trial of OROS® methylphenidate (CONCERTA®) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82–90.
29. GrcevichS.SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs. 2001;10(11):2003–11.
30. PelhamWE, WalkerJL, SturgesJ, HozaJ.Comparative effects of methylphenidate on ADD girls and boys. J Am Acad Child Adolesc Psychiatry. 1989;28(5):773–6.
31. CharachA, IckowiczA, SchacharR.Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559–67.
32. BarbaresiWJ, KatusicSK, ColliganRC, et al. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1–10.
33. SwansonJM, ElliottGR, GreenhillLL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015–27.
34. PoultonA, CowellCT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health. 2003;39:180–5.
35. MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762–9.
36. LisskaMC, RivkeesSA. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab. 2003;16(5):711–18.
37. SwansonJ, GreenhillL, WigalT, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–13.
38. SpencerTJ, BiedermanJ, HardingM, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35(11):1460–9.
39. FaraoneSV, BiedermanJ, MorleyCP, SpencerTJ.Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009.
40. PidsosnyIC, ViraniA. Pediatric psychopharmacology update: psychostimulants and tics – past, present, and future. J Can Acad Child Adolesc Psychiatry. 2006;15(2):84–6.
41. LawSF, SchacharRJ. Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficity hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 1999;38(8):944–51.
42. PalumboD, SpencerT, LynchJ, Co-ChienH, FaraoneSV.Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol. 2004;14(2):185–94.
43. BiedermanJ, LopezFA, BoellnerSW, ChandlerMC.A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 in children with attention deficit hyperactivity disorder. Pediatrics. 2002;110(2):258–66.
44. WolraichML, GreenhillLL, PelhamW, et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883–92.
45. GadowKD, SverdJ, SprafkinJ, NolanEE, GrossmanS.Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56:330–6.
46. Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58:527–36.
47. NolanEE, GadowKD, SprafkinJ.Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics. 1999;103(4):730–7.
48. WilensT, SpencerT, PrinceJ, BiedermanJ.Stimulants and sudden death: what is a physician to do?Pediatrics. 2006;118(3):1215–19.
49. FDA. Communication about an ongoing safety review of stimulant medication used in children with attention-deficit/hyperactivity disorder (ADHD). In: FDA US, ed.; 2009.
50. GouldMS, WalshTB, MunfakhJL, et al. Sudden death and use of stimulant medications in youths. 2009 [updated 2009; cited 2009 Aug 28]; 922–1001]. Available from: http://ajp.psychiatryonline.org/cgi/reprint/ajp;166/9/992.
51. BesagFM. Is suicidality serious? Curr Drug Saf. 2009;4(2):95–6.
52. PerrinJM, FriedmanRA, KnilansTK.Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122(2):451–3.
53. VetterVL, EliaJ, EricksonC, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]. A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;120(7):e55–9.
54. MosholderAD, GelperinK, HammadTK, PhelanK, Johann-LiangR.Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pedatrics. 2009;123:611–16.
55. El-ZeinRA, Abdel-RahmanSZ, HayMJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005;230(2):284–91.
56. DunnickJK, HaileyJR.Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology. 1995;103:77–84.
57. SelbyJV, FriedmanGD, FiremanBH.Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res. 1989;49(20):5736–47.
58. Center for the Evaluation of Risks to Human Reproduction NTP. NTP-CERHR monograph on the potential human reproductive and developmental effects of methylphenidate. NIH Publication No. 05–4473; 2005.
59. PonsaI, Ramos-QuirogaJA, RibasesM, et al. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat Res. 2009;666(1–2):44–9.
60. WilensT, FaraoneS, BiedermanJ, GunawardeneS.Does stimulant therapy of ADHD beget later substance abuse: a meta-analytic review of the literature. Pediatrics. 2003;11(1):179–85.
61. KatusicSK, BarbaresiWJ, ColliganRC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005;15(5):764–76.
62. WilensT, AdamsonJ, MonuteauxMC, et al. Effect of prior stimulant treatment for attention-deficit hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med. 2008;162(10):916–21.
63. BiedermanJ, MonuteauxMC, SpencerT, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597–603.
64. MannuzzaS, KleinRG, TruongNL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry. 2008;165(5):604–9.
65. WilensTE, AdlerLA, AdamsonJ, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31.
66. WilensTE, GignacM, SwezeyA, MonuteauxMC, BiedermanJ. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry. 2006;45(4):408–14.
67. McCabeSE, KnightJR, TeterCJ, WechslerH.Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;99(1):96–106.
68. TeterCJ, McCabeSE, LaGrangeK, CranfordJA, BoydCJ.Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26(10):1501–10.
69. McCabeSE, TeterCJ, BoydCJ.The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095–116.
70. PoulinC.From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction. 2007;102(5):740–51.
71. BiedermanJ, FaraoneSV, SpencerT, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:1792–8.
72. WilloughbyMT, CurranPJ, CostelloEJ, AngoldA. Implications of early versus late onset of attention-deficit/hyperactivity disorder symptoms. J Am Acad Child Adolesc Psychiatry. 2000;39(12):1512–19.
73. NandagopalJJ, DelBelloMP, KowatchR.Pharmacologic treatment of pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2003;18:455–69.
74. JoshiG, WilensT. Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am. 2009;18(2):291–319, vii–viii.
75. WozniakJ, BiedermanJ, KielyK, et al. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995;34:867–76.
76. SchefferRE, KowatchRA, CarmodyT, RushAJ.Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005;162:58–64.
77. FindlingRL, ShortEJ, McNamaraNK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1445–53.
78. DelBelloMP, SoutulloCA, HendricksW, et al. Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord. 2001;3(2):53–7.
79. QuintanaH, BirmaherB, StedgeD, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25(3):283–94.
80. HandenBL, JohnsonCR, LubetskyM.Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30(3):245–55.
81. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266–74.
82. PoseyDJ, AmanMG, McCrackenJT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4):538–44.
83. StiglerKA, DesmondLA, PoseyDJ, WiegandRE, McDougleCJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(1):49–56.
84. DaviesS, HeymanI, GoodmanR.A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003;45:292–5.
85. HermanBH, JonesJ, DabbsK, et al. The frequency, complications, and aetiology of ADHD in new onset paediatric epilepsy. Brain. 2007;130:3135–48.
86. Baptista-NetoL, DoddsA, RaoS, et al. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs. 2008;17(1):77–84.
87. McAfeeAT, HoldridgeKC, JohannesCB, HornbuckleK, WalkerAM. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims data. Curr Drug Saf. 2008;3(2):123–31.
88. Gonzalez-HeydrichJ, WaberJ, WaberD, et al. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav. 2010;18(3):229–37.
89. DavissWB, BirmaherB, DilerRS, MintzJ. Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression?J Child Adolesc Psychopharmacol. 2008;18(3):257–64.
90. BiedermanJ, MonuteauxMC, SpencerT, WilensTE, FaraoneSV.Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;124(1):71–8.